It’s not hard to imagine AbbVie’s management team presented with PowerPoint decks showing overall response rates of 44% in patients with high expression of the protein DLL3, perhaps with the ...

Early drug development attempts ran into problems, however, most notably when AbbVie abandoned the development of Rova-T, an anti-DLL3 ADC acquired as part of a $5.8 billion takeover of Stemcentrx ...